ARCH's passive stake is unchanged, indicating no shift in investor sentiment. Monitor for any future conversion to a 13D filing, which would signal activist intent, but no such signal is present here.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $16.86entry
- T+1 · 5d ago −7.24%α −6.88% · $15.64
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ARCH Venture Fund IX, L.P. and affiliated entities filed an amended Schedule 13G disclosing a 17.4% passive stake in Lyell Immunopharma as of November 4, 2026, unchanged from the prior filing. The filing confirms the investor remains a passive holder with no change in position or intent, following the company's recent $80M private placement and Q3 earnings report.
Key Financial Metrics
Key Facts
- ARCH Venture Fund IX and related entities hold 5,568,424 shares of Lyell Immunopharma common stock, representing 17.4% of shares outstanding as of November 4, 2026.
- The stake percentage is based on 24,585,565 shares outstanding as of October 30, 2026, plus 7,428,040 shares sold in a private placement on November 4, 2026.
- The filing is an amendment to Schedule 13G, confirming passive investor status with no change in beneficial ownership from the prior filing.
- The filing date is November 10, 2026, six days after the company's Q3 2026 earnings release and $80M private placement.
Financial Impact
No change in stake; ARCH's 17.4% holding is valued at approximately $63.5M based on the $365M market cap.
Risk Factors
- No material risks identified from this filing; the passive stake is routine and unchanged.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001012975-26-001025 |
| Document: 0001012975-26-001025-index.html | 0001012975-26-001025 |
| Document: 0001012975-26-001025.txt | 0001012975-26-001025 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Viewing Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers